{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:58:30Z","timestamp":1774958310959,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health & Welfare","award":["RS-2024-004370388"],"award-info":[{"award-number":["RS-2024-004370388"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04263-1","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:14:44Z","timestamp":1774955684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mass cytometry uncovers distinct blood myeloid phenotypes linked to clinical responses during gastric cancer chemoimmunotherapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Sung Hee","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minae","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyeon","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"10294","key":"4263_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340. https:\/\/doi.org\/10.1016\/s0140-6736(21)00797-2","journal-title":"Lancet"},{"issue":"11","key":"4263_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/s1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24(11):1181\u20131195. https:\/\/doi.org\/10.1016\/s1470-2045(23)00515-6","journal-title":"Lancet Oncol"},{"key":"4263_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K et al (2024) Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ 385:e078876. https:\/\/doi.org\/10.1136\/bmj-2023-078876","journal-title":"BMJ"},{"issue":"5","key":"4263_CR4","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/2159-8290.Cd-23-0857","volume":"14","author":"M An","year":"2024","unstructured":"An M, Mehta A, Min BH et al (2024) Early immune remodeling steers clinical response to first-line chemoimmunotherapy in advanced gastric cancer. Cancer Discov 14(5):766\u2013785. https:\/\/doi.org\/10.1158\/2159-8290.Cd-23-0857","journal-title":"Cancer Discov"},{"key":"4263_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179414","author":"HJ An","year":"2021","unstructured":"An HJ, Chon HJ, Kim C (2021) Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22179414","journal-title":"Int J Mol Sci"},{"key":"4263_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840207","volume":"13","author":"DA Barth","year":"2022","unstructured":"Barth DA, Stanzer S, Spiegelberg JA et al (2022) Patterns of peripheral blood B-cell subtypes are associated with treatment response in patients treated with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study. Front Immunol 13:840207. https:\/\/doi.org\/10.3389\/fimmu.2022.840207","journal-title":"Front Immunol"},{"key":"4263_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973402","volume":"12","author":"JM Lavoie","year":"2022","unstructured":"Lavoie JM, Baichoo P, Chavez E et al (2022) Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. Front Oncol 12:973402. https:\/\/doi.org\/10.3389\/fonc.2022.973402","journal-title":"Front Oncol"},{"issue":"5","key":"4263_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1127","volume":"9","author":"M Wang","year":"2020","unstructured":"Wang M, Huang YK, Kong JC et al (2020) High-dimensional analyses reveal a distinct role of T-cell subsets in the immune microenvironment of gastric cancer. Clin Transl Immunol 9(5):e1127. https:\/\/doi.org\/10.1002\/cti2.1127","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"4263_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","volume":"8","author":"Z Liu","year":"2023","unstructured":"Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, Cheng Q, Luo P, Zhang Y, Han X (2023) Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther 8(1):200. https:\/\/doi.org\/10.1038\/s41392-023-01451-2","journal-title":"Signal Transduct Target Ther"},{"key":"4263_CR10","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","volume":"19","author":"M Andreatta","year":"2021","unstructured":"Andreatta M, Carmona SJ (2021) UCell: robust and scalable single-cell gene signature scoring. Comput Struct Biotechnol J 19:3796\u20133798. https:\/\/doi.org\/10.1016\/j.csbj.2021.06.043","journal-title":"Comput Struct Biotechnol J"},{"issue":"62","key":"4263_CR11","doi-asserted-by":"publisher","first-page":"106071","DOI":"10.18632\/oncotarget.22526","volume":"8","author":"M Hosono","year":"2017","unstructured":"Hosono M, Koma YI, Takase N et al (2017) CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells. Oncotarget 8(62):106071\u2013106088. https:\/\/doi.org\/10.18632\/oncotarget.22526","journal-title":"Oncotarget"},{"issue":"12","key":"4263_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25(12):677\u2013686. https:\/\/doi.org\/10.1016\/j.it.2004.09.015","journal-title":"Trends Immunol"},{"issue":"5","key":"4263_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.4161\/onci.20171","volume":"1","author":"A Pinto","year":"2012","unstructured":"Pinto A, Rega A, Crother TR, Sorrentino R (2012) Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology 1(5):726\u2013734. https:\/\/doi.org\/10.4161\/onci.20171","journal-title":"Oncoimmunology"},{"issue":"1","key":"4263_CR14","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1038\/s41467-022-32570-z","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, Jia K, Sun Y et al (2022) Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat Commun 13(1):4851. https:\/\/doi.org\/10.1038\/s41467-022-32570-z","journal-title":"Nat Commun"},{"key":"4263_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005509","author":"H Kim","year":"2023","unstructured":"Kim H, Park S, Han KY et al (2023) Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005509","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4263_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.Cir-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, Shin DS, Zaretsky J et al (2016) PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res 4(3):194\u2013203. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0210","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"4263_CR17","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41467-024-46148-4","volume":"15","author":"K Miyake","year":"2024","unstructured":"Miyake K, Ito J, Takahashi K, Nakabayashi J, Brombacher F, Shichino S, Yoshikawa S, Miyake S, Karasuyama H (2024) Single-cell transcriptomics identifies the differentiation trajectory from inflammatory monocytes to pro-resolving macrophages in a mouse skin allergy model. Nat Commun 15(1):1666. https:\/\/doi.org\/10.1038\/s41467-024-46148-4","journal-title":"Nat Commun"},{"issue":"25","key":"4263_CR18","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMoa051424","volume":"353","author":"F Pag\u00e8s","year":"2005","unstructured":"Pag\u00e8s F, Berger A, Camus M et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654\u20132666. https:\/\/doi.org\/10.1056\/NEJMoa051424","journal-title":"N Engl J Med"},{"issue":"5","key":"4263_CR19","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3892\/or.2013.2302","volume":"29","author":"K Wakatsuki","year":"2013","unstructured":"Wakatsuki K, Sho M, Yamato I, Takayama T, Matsumoto S, Tanaka T, Migita K, Ito M, Hotta K, Nakajima Y (2013) Clinical impact of tumor-infiltrating CD45RO\u207a memory T cells on human gastric cancer. Oncol Rep 29(5):1756\u20131762. https:\/\/doi.org\/10.3892\/or.2013.2302","journal-title":"Oncol Rep"},{"issue":"5","key":"4263_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G et al (2018) Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment. Cell 174(5):1293-1308.e1236. https:\/\/doi.org\/10.1016\/j.cell.2018.05.060","journal-title":"Cell"},{"key":"4263_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00514","volume":"5","author":"P Italiani","year":"2014","unstructured":"Italiani P, Boraschi D (2014) From monocytes to M1\/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol 5:514. https:\/\/doi.org\/10.3389\/fimmu.2014.00514","journal-title":"Front Immunol"},{"issue":"1","key":"4263_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2050-7771-2-1","volume":"2","author":"J Yang","year":"2014","unstructured":"Yang J, Zhang L, Yu C, Yang XF, Wang H (2014) Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2(1):1. https:\/\/doi.org\/10.1186\/2050-7771-2-1","journal-title":"Biomark Res"},{"issue":"3","key":"4263_CR23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R et al (2021) A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184(3):792-809.e723. https:\/\/doi.org\/10.1016\/j.cell.2021.01.010","journal-title":"Cell"},{"issue":"5","key":"4263_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.20892\/j.issn.2095-3941.2024.0589","volume":"22","author":"T Wang","year":"2025","unstructured":"Wang T, Liu C, Hu X, Yang N, Qiu C (2025) Senescent macrophages in cancer: roles in tumor progression and treatment opportunities. Cancer Biol Med 22(5):439\u2013459. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0589","journal-title":"Cancer Biol Med"},{"key":"4263_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2018.00049","volume":"8","author":"AR Poh","year":"2018","unstructured":"Poh AR, Ernst M (2018) Targeting macrophages in cancer: from bench to bedside. Front Oncol 8:49. https:\/\/doi.org\/10.3389\/fonc.2018.00049","journal-title":"Front Oncol"},{"issue":"1","key":"4263_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100776","volume":"8","author":"B Fendl","year":"2023","unstructured":"Fendl B, Berghoff AS, Preusser M, Maier B (2023) Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy. ESMO Open 8(1):100776. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100776","journal-title":"ESMO Open"},{"issue":"1","key":"4263_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R (2022) Liquid biopsy: current technology and clinical applications. J Hematol Oncol 15(1):131. https:\/\/doi.org\/10.1186\/s13045-022-01351-y","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04263-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04263-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04263-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:14:45Z","timestamp":1774955685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04263-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4263"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04263-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"31 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed and approved by the Institutional Review Board (IRB) of Samsung Medical Center (Seoul, Korea; IRB No. 2019\u201311-089).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent has been obtained from the patients to publish this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"128"}}